Skip to main content
Hunan Jingfeng Pharmaceutical Co.,Ltd. logo

Hunan Jingfeng Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000908 ISIN · CNE000000Y11 LEI · 83680029LIJEDRQHLO62 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,637 across all filing types
Latest filing 2026-05-21 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 000908

About Hunan Jingfeng Pharmaceutical Co.,Ltd.

https://www.jfyiyao.com

Hunan Jingfeng Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company focuses on therapeutic areas including cardiovascular and cerebrovascular diseases, orthopedics, and oncology. Its product portfolio features specialized treatments such as Erigeron Breviscapus injections for cardiovascular health and sodium hyaluronate injections for joint health and surgical applications. The firm operates multiple production bases and research centers, emphasizing the integration of chemical drugs, biological products, and traditional Chinese medicine derivatives. By leveraging advanced formulation technologies, the company aims to provide high-quality generic and innovative medications. Its operations encompass the entire value chain from active pharmaceutical ingredient (API) production to finished dosage forms, targeting both clinical and retail markets.

Recent filings

Filing Released Lang Actions
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is an official announcement of the resolutions passed at the 2025 annual shareholders’ meeting, detailing each proposal and the vote counts (for/against/abstain). This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-21 Chinese
关于申请撤销其他风险警示的进展公告
Regulatory Filings Classification · 90% confidence The document is a progress announcement regarding the application to remove a stock risk warning, submitted to the Shenzhen Stock Exchange. It is a routine regulatory update about listing compliance, not a financial report, management change, or other specific category. It fits the general regulatory announcement fallback category.
2026-05-21 Chinese
广东崇立律师事务所关于石药集团湖南景峰医药股份有限公司2025年度股东会的法律意见书
Regulatory Filings Classification · 93% confidence The document is a lawyer’s legal opinion letter (“法律意见书”) verifying the convening procedures, voting eligibility, vote counting process, and final voting results of the company’s 2025 annual shareholders’ meeting. It is not a presentation, earnings release, proxy solicitation statement, or formal vote‐result announcement issued by the company itself, but rather a compliance/legal attestation filed alongside the meeting materials. It does not contain substantive financial statements nor solicit proxies, so it does not qualify as an Annual Report, Interim Report, Proxy Statement, or Voting Results Announcement. It best fits as a general regulatory/compliance filing by a third party. Therefore, it should be classified under Regulatory Filings (RNS).
2026-05-21 Chinese
关于2025年度股东会增加临时提案暨股东会补充通知的公告
AGM Information Classification · 95% confidence The document is a detailed announcement regarding the addition of a temporary proposal to the 2025 Annual General Meeting (AGM) of the company 石药集团湖南景峰医药股份有限公司. It includes information about the meeting date, voting procedures, proposal details, and proxy forms. The content focuses on the organization and notification of the AGM, including shareholder voting instructions and meeting logistics. There is no financial data, earnings information, or audit content. The document is not a report itself but a formal notice and supplementary information related to the AGM. Therefore, it fits the category of AGM Information (AGM-R). The document length is 4608 characters, which is consistent with a detailed AGM notice rather than a full report or announcement of report publication.
2026-05-06 Chinese
关于股东提议增加股东会临时提案的公告
Board/Management Information Classification · 95% confidence The document is an announcement from the board of directors regarding a shareholder proposal to add a temporary agenda item for the upcoming 2025 Annual General Meeting (AGM). It details the proposal to elect a new non-independent director, including the nominee's background and compliance with relevant laws and regulations. The document does not contain financial statements or detailed financial analysis, nor is it a transcript or presentation. It is a formal announcement related to board and shareholder meeting matters, specifically about a board nomination proposal for the AGM. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or proposals related to the company's board of directors or senior management.
2026-05-06 Chinese
2025年度独立董事述职报告（钟少先）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2025, authored by an independent director of the company. It details the director's duties, attendance at board and committee meetings, communication with auditors, involvement in governance and compliance, and evaluation of company reports and management appointments. The content focuses on the director's performance and oversight activities during the year, rather than presenting financial statements or audit opinions themselves. It is a formal report on the director's work and governance role, not a financial report or audit report. This type of document fits best under Board/Management Information (MANG), as it relates to management and board activities and changes, including director duties and evaluations. The document length is sufficient and contains detailed narrative about board and management activities, not just an announcement or certification. Therefore, the classification is MANG with high confidence.
2026-04-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.